View in EDS

Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.

Saved in:
Bibliographic Details
Title: Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Authors: Zoeller JJ; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, 240 Longwood Avenue, Boston, MA, 02115, USA., Vagodny A; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, 240 Longwood Avenue, Boston, MA, 02115, USA., Daniels VW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Taneja K; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA., Tan BY; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA., DeRose YS; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Fujita M; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Welm AL; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Leverson JD; Oncology Development, AbbVie, North Chicago, IL, USA., Blot V; Oncology Development, AbbVie, North Chicago, IL, USA., Bronson RT; Department of Pathology, Harvard Medical School, Boston, MA, USA., Dillon DA; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA., Brugge JS; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, 240 Longwood Avenue, Boston, MA, 02115, USA. joan_brugge@hms.harvard.edu.
Source: Breast cancer research : BCR [Breast Cancer Res] 2020 Nov 30; Vol. 22 (1), pp. 132. Date of Electronic Publication: 2020 Nov 30.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33256808
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zoeller+JJ%22">Zoeller JJ</searchLink>; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, 240 Longwood Avenue, Boston, MA, 02115, USA.<br /><searchLink fieldCode="AU" term="%22Vagodny+A%22">Vagodny A</searchLink>; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, 240 Longwood Avenue, Boston, MA, 02115, USA.<br /><searchLink fieldCode="AU" term="%22Daniels+VW%22">Daniels VW</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Taneja+K%22">Taneja K</searchLink>; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tan+BY%22">Tan BY</searchLink>; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22DeRose+YS%22">DeRose YS</searchLink>; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Fujita+M%22">Fujita M</searchLink>; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Welm+AL%22">Welm AL</searchLink>; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Letai+A%22">Letai A</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Leverson+JD%22">Leverson JD</searchLink>; Oncology Development, AbbVie, North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Blot+V%22">Blot V</searchLink>; Oncology Development, AbbVie, North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Bronson+RT%22">Bronson RT</searchLink>; Department of Pathology, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Dillon+DA%22">Dillon DA</searchLink>; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Brugge+JS%22">Brugge JS</searchLink>; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, 240 Longwood Avenue, Boston, MA, 02115, USA. joan_brugge@hms.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100927353%22">Breast cancer research : BCR</searchLink> [Breast Cancer Res] 2020 Nov 30; Vol. 22 (1), pp. 132. <i>Date of Electronic Publication: </i>2020 Nov 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central+Ltd%22">BioMed Central Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100927353 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1465-542X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214655411%22">14655411 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33256808
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s13058-020-01374-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 132
    Titles:
      – TitleFull: Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zoeller JJ
      – PersonEntity:
          Name:
            NameFull: Vagodny A
      – PersonEntity:
          Name:
            NameFull: Daniels VW
      – PersonEntity:
          Name:
            NameFull: Taneja K
      – PersonEntity:
          Name:
            NameFull: Tan BY
      – PersonEntity:
          Name:
            NameFull: DeRose YS
      – PersonEntity:
          Name:
            NameFull: Fujita M
      – PersonEntity:
          Name:
            NameFull: Welm AL
      – PersonEntity:
          Name:
            NameFull: Letai A
      – PersonEntity:
          Name:
            NameFull: Leverson JD
      – PersonEntity:
          Name:
            NameFull: Blot V
      – PersonEntity:
          Name:
            NameFull: Bronson RT
      – PersonEntity:
          Name:
            NameFull: Dillon DA
      – PersonEntity:
          Name:
            NameFull: Brugge JS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 11
              Text: 2020 Nov 30
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1465-542X
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Breast cancer research : BCR
              Type: main
ResultId 1